519 related articles for article (PubMed ID: 32987799)
1. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.
Seliger B; Massa C; Yang B; Bethmann D; Kappler M; Eckert AW; Wickenhauser C
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987799
[TBL] [Abstract][Full Text] [Related]
2. Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach.
Merlano MC; Denaro N; Garrone O
Curr Opin Oncol; 2020 May; 32(3):203-209. PubMed ID: 32195680
[TBL] [Abstract][Full Text] [Related]
3. Tumor immune microenvironment in head and neck cancers.
Chen SMY; Krinsky AL; Woolaver RA; Wang X; Chen Z; Wang JH
Mol Carcinog; 2020 Jul; 59(7):766-774. PubMed ID: 32017286
[TBL] [Abstract][Full Text] [Related]
4. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB
Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Head and Neck Cancer.
Sim F; Leidner R; Bell RB
Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002
[TBL] [Abstract][Full Text] [Related]
6. The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.
Outh-Gauer S; Morini A; Tartour E; Lépine C; Jung AC; Badoual C
Head Neck Pathol; 2020 Jun; 14(2):330-340. PubMed ID: 32124416
[TBL] [Abstract][Full Text] [Related]
7. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
[TBL] [Abstract][Full Text] [Related]
8. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
10. The biology of combination immunotherapy in recurrent metastatic head and neck cancer.
Yuan X; Yi M; Zhang W; Xu L; Chu Q; Luo S; Wu K
Int J Biochem Cell Biol; 2021 Jul; 136():106002. PubMed ID: 33962022
[TBL] [Abstract][Full Text] [Related]
11. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
[TBL] [Abstract][Full Text] [Related]
12. The promise of immunotherapy in head and neck squamous cell carcinoma.
Economopoulou P; Agelaki S; Perisanidis C; Giotakis EI; Psyrri A
Ann Oncol; 2016 Sep; 27(9):1675-85. PubMed ID: 27380958
[TBL] [Abstract][Full Text] [Related]
13. Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
Farlow JL; Brenner JC; Lei YL; Chinn SB
Oral Oncol; 2021 Sep; 120():105420. PubMed ID: 34218062
[TBL] [Abstract][Full Text] [Related]
14. The head and neck cancer genome in the era of immunotherapy.
Wijetunga NA; Yu Y; Morris LG; Lee N; Riaz N
Oral Oncol; 2021 Jan; 112():105040. PubMed ID: 33197752
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
[TBL] [Abstract][Full Text] [Related]
16. HNSCC: Tumour Antigens and Their Targeting by Immunotherapy.
von Witzleben A; Wang C; Laban S; Savelyeva N; Ottensmeier CH
Cells; 2020 Sep; 9(9):. PubMed ID: 32942747
[TBL] [Abstract][Full Text] [Related]
17. Immune microenvironment of human papillomavirus-positive head and neck squamous cell carcinoma.
Zhu D; He X; Li Y; Li G; Chen M
Sci Prog; 2024; 107(1):368504241237888. PubMed ID: 38545800
[TBL] [Abstract][Full Text] [Related]
18. The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.
Freiser ME; Serafini P; Weed DT
Immunol Res; 2013 Dec; 57(1-3):52-69. PubMed ID: 24218361
[TBL] [Abstract][Full Text] [Related]
19. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX
Front Immunol; 2021; 12():791621. PubMed ID: 35003112
[TBL] [Abstract][Full Text] [Related]
20. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
